Table 6.
Repeated bivariate cox regression models for risk of death in the cohort
| TAPSE ≤18 mm | Hazard ratio (95% confidence interval) |
P |
|---|---|---|
| Unadjusted | 4.8 (2.0–11.3) | 0.005 |
| Adjusted for | ||
| Age | 4.6 (1.4–15.7) | 0.01 |
| Race | 5.0 (1.5–17.0) | 0.01 |
| NYHA | 4.3 (1.3–14.7) | 0.02 |
| Treatment status | 5.3 (1.5–18.3) | 0.008 |
| Disease type (IPAH vs. SSc-PAH) | 5.8 (1.7–20.3) | 0.006 |
| RVFS | 3.9 (0.9–17.9) | 0.08 |
| RVFAC | 3.4 (0.8–14.4) | 0.10 |
| RVEF | 4.5 (1.3–15.5) | 0.02 |
| LVEDVI | 4.0 (1.1–14.5) | 0.04 |
| VMI | 4.6 (1.3–15.8) | 0.01 |
| Cardiac index | 4.2 (1.2–14.8) | 0.03 |
| SVI | 4.4 (1.2–15.6) | 0.02 |
| PVR | 4.1 (1.2–14.2) | 0.03 |
Note
IPAH: ideopathic pulmonary arterial hypertension; LVEDVI: left ventricular end-diastolic volume index; NYHA: New York Health Association; PVR: pulmonary vascular resistance; RVEF: right ventricular ejection fraction; RVFAC: right ventricular fraction area change; RVFS: right ventricular fraction shortening; SSc-PAH: scleroderma-related pulmonary arterial hypertension; SVI: stroke volume index; TAPSE: tricuspid annular plane systolic excursion; VMI: volume mass index.